Fredrik Schjesvold, MD, PhD, Discusses the Rationale for the OCEAN Trial in Relapsed/Refractory Multiple Myeloma


Fredrik Schjesvold, MD, PhD, speaks about the FDA approval of melflufen in relapsed/refractory multiple myeloma and its next phase of development at the 2021 International Myeloma Workshop.

At the 2021 International Myeloma Workshop, CancerNetwork® spoke with Fredrik Schjesvold, MD, PhD, founder and head of the Oslo Myeloma Center, about the rationale for the phase 3 OCEAN trial (NCT03151811), and why investigators decided to examine melflufen (Pepaxto) in combination with dexamethasone compared with pomalidomide (Pomalyst)/dexamethasone in patients with relapsed/refractory multiple myeloma.


The rationale [behind the] OCEAN trial was to take the drug melflufen that was already approved in the [United States] for patients who have received at least 4 previous lines of treatment. The next phase in the development of treatment was to compare this in an earlier line of treatment [with] the standard pomalidomide/dexamethasone in patients who are already lenalidomide [Revlimid] refractory and exposed to proteasome inhibitors. …The study was to show that [melflufen/dexamethasone is better than pomalidomide/dexamethasone.


Schjesvold F, Dimopoulos MA, Delimpasi S, et al. OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of melflufen and dexamethasone (Dex) versus pomalidomide (Pom) and dex in relapsed refractory multiple myeloma (RRMM). Presented at: International Myeloma Workshop; September 8-11, 2021; Vienna, Austria. Accessed September 11, 2021.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Related Content